CurveBeam AI (ASX:CVB) prints two POs and 0.67 quarters of cash

A A$5m placement buys time, but NMPA clearance in H2 is now the whole thesis

CurveBeam AI (ASX:CVB) has released its Q4 FY26 Appendix 4C, and the quarter reads like a company caught between two timelines. Only two HiRise purchase orders landed, one in the US and one to WEGO in China, with several advanced opportunities slipping into Q1 FY27.

Customer receipts jumped 80% quarter on quarter to A$2.58 million, and operating cash burn fell 42% to A$2.43 million. So the business is throwing off more cash while spending less of it. That is the direction of travel a small-cap medtech needs to show.

The problem is the balance sheet. CurveBeam closed the quarter with A$1.64 million of cash, which the Appendix 4C calculates as just 0.67 quarters of runway. A A$5 million placement lifts the pro-forma position to A$6.64 million, or roughly 2.7 quarters.

The whole investment case now leans on one date. NMPA clearance in China in the second half of calendar 2026, which triggers a A$1 million milestone from Weiying/WEGO and unlocks the initial order for US-manufactured HiRise systems.

Two POs is a slow quarter, but the receipts line tells a different story

Purchase orders are the metric CurveBeam has trained the market to watch, and two devices is a thin print. Management flagged that several advanced deals did not close before 30 June and remain active, which is the kind of language that either delivers in Q1 or quietly disappears.

The receipts number is more encouraging. A$2.58 million represents an 80% jump on Q3, driven by the two-to-six month lag between PO signing, install and payment. In plain English, receipts hitting the bank this quarter reflect sales momentum from earlier periods.

We think the receipts line matters more than the PO line right now because it is the number that actually funds operations. But investors should not confuse a strong collection quarter with a strong sales quarter. The order book carried into Q1 FY27 is A$4.2 million, down from A$4.8 million entering Q4.

The China milestone stack is the reason to still own this

The Weiying/WEGO partnership is where the long-dated value sits. NMPA clearance triggers A$1 million. The first 10 HiRise sales in China trigger another A$1 million, and the first 50 sales trigger a further A$2 million.

As we covered in our previous coverage of the ODI approval, the regulatory and capital-transfer risks around the Chinese leg of this partnership are already cleared. What remains is the NMPA clock and the launch execution. Management continues to guide to H2 CY26 for clearance, which now sits within the next six months.

Commercial prep is running in parallel. Key opinion leader outreach, reference site identification and training of Weiying personnel on manufacturing and service processes are all underway. That is the sequence you want to see so the market launch begins the day clearance lands.

Robotic surgery validation is quietly becoming the second leg

The validation work with the leading robotic surgery platform advanced this quarter. All five HiRise datasets met the vendor’s image quality, segmentation and landmark requirements, putting the scans on par with traditional supine MDCT data.

The more interesting development is a second robotic surgery platform now in validation, and the expansion of scope from total knee to total hip arthroplasty. That widens the addressable market for HiRise inside robotic orthopaedics, which is growing faster than underlying joint replacement volumes.

The Investors Takeaway for CurveBeam AI

The Q4 numbers are a mixed read. Improving cash discipline and stronger receipts on one side, thin new orders and a stretched balance sheet on the other. The A$5 million placement buys roughly 2.7 quarters of pro-forma runway, which lines up almost exactly with the window in which NMPA clearance is expected to arrive.

That is not a coincidence. The whole capital structure is now sequenced around clearing the Chinese regulator and banking the milestone payments that follow. Investors can revisit our previous coverage of the China ODI approval at stocksdownunder.

Our concern is that this business now has almost no margin for error on the China timeline, and the robotic surgery validation, while progressing, will not move the P&L in FY27. The bull case still stands, but it runs through a single regulator’s inbox.